Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?
Axsome is posting 65% revenue growth but burning cash, while Moderna's vaccine market is cooling yet its oncology pipeline carries transformative potential.
Overview
Choosing between Axsome Therapeutics (NASDAQ:AXSM) and Moderna (NASDAQ:MRNA) requires weighing a focused neuroscience portfolio against a broad, potentially revolutionary technology platform that is currently navigating a period of transition.
Axsome focuses on developing therapies for central nervous system disorders, with several products already on the market. Moderna uses its messenger RNA technology to develop vaccines and treatments, attempting to replicate its success in infectious diseases across new areas like oncology and rare diseases.
Details
Axsome operates in the competitive world of biotech stocks, focusing specifically on central nervous system (CNS) conditions. The company currently commercializes Auvelity for major depressive disorder and Sunosi for narcolepsy within the United States. Its growth strategy is bolstered by the 2025 FDA approval of Symbravo for migraine treatment, alongside licensing deals with companies like Pharmanovia to expand its reach into Europe and the Middle East.
Source
Originally published at www.fool.com.